A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years

NCT07054099 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

474

Enrollment

INDUSTRY

Sponsor class

Conditions

Varicella (Chickenpox)
Chickenpox Vaccine

Interventions

BIOLOGICAL: MG1111 (Barycela inj.)
BIOLOGICAL: VARIVAX™

Sponsor

GC Biopharma Corp